Adverse event profile with once-monthly oral ibandronate: The MOBILE study long-term extension.

被引：0
|
作者：
Silverman, S.
Emkey, R.
Reginster, J. Y.
Lorenc, R.
Hughes, C.
Kendler, D.
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Radiant Res, Wyomissing, PA USA
[3] Univ Liege, B-4000 Liege, Belgium
[4] Childrens Mem Inst, Warsaw, Poland
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Univ British Columbia, Osteoporosis Res Ctr, Vancouver, BC V5Z 1M9, Canada
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S418 / S418
页数：1
相关论文
共 50 条
  • [1] Efficacy and adverse event profile of once-monthly oral ibandronate: Year 1 of the mobile long-term extension study
    Emkey, Ronald D.
    Miller, Paul D.
    Sedarati, Farhad
    Silverman, Stuart L.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S220 - S220
  • [2] Progressive bone density gains with once-monthly oral Ibandronate: The MOBILE study long-term extension.
    Lewiecki, E. Michael
    Reginster, Jean-Yves
    Elizondo-Alanis, Luis J.
    Neate, Colin
    Adami, Silvano
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S584 - S584
  • [3] The MOBILE study long-term extension: Progressive bone density gains with 150mg once-monthly oral ibandronate.
    Miller, P. D.
    Luckey, M.
    Cooper, C.
    Stakkestad, J. A.
    Hughes, C.
    Bolognese, M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S417 - S417
  • [4] Safety profile of once-monthly oral ibandronate: MOBILE 2-year results
    Bolognese, M
    Luckey, M
    Miller, P
    Civitelli, R
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 793 - 793
  • [5] Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study
    Miller, P. D.
    Recker, R. R.
    Reginster, J. -Y.
    Riis, B. J.
    Czerwinski, E.
    Masanauskaite, D.
    Kenwright, A.
    Lorenc, R.
    Stakkestad, J. A.
    Lakatos, P.
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 (06) : 1747 - 1756
  • [6] Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study
    P. D. Miller
    R. R. Recker
    J.-Y. Reginster
    B. J. Riis
    E. Czerwinski
    D. Masanauskaite
    A. Kenwright
    R. Lorenc
    J. A. Stakkestad
    P. Lakatos
    Osteoporosis International, 2012, 23 : 1747 - 1756
  • [7] The MOBILE study long-term extension: Continuing improvements in efficacy with monthly oral ibandronate (150 mg)
    Lewiecki, E. M.
    Sedarati, F.
    Neate, C.
    Lorenc, R.
    BONE, 2007, 40 (06) : S302 - S302
  • [8] Response to once-monthly and daily oral ibandronate in the mobile study: 2-year analysis
    不详
    CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S145 - S145
  • [9] Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study
    Naber, Dieter
    Baker, Ross A.
    Eramo, Anna
    Forray, Carlos
    Hansen, Karina
    Sapin, Christophe
    Peters-Strickland, Timothy
    Nylander, Anna-Greta
    Hertel, Peter
    Schmidt, Simon Nitschky
    Loze, Jean-Yves
    Potkin, Steven G.
    SCHIZOPHRENIA RESEARCH, 2018, 192 : 205 - 210
  • [10] The efficacy of monthly oral ibandronate (150mg) 15 maintained: Mobile study long-term extension
    Stepan, J.
    Riis, B. J.
    Sedarati, F.
    Neate, C.
    Felsenberg, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 533 - 533
12345